Elanco Animal Health

ELAN

Market cap $11.6B

MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.

The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.

EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovation Action reinforces the FDA's commitment to act swiftly against emerging animal health threats Scientific studies showed Credelio CAT may be effective in treating New World screwworm in catsi,ii Preventing open wounds through effective flea and tick control is critical in protecting pets from NWS INDIANAPOLIS , Nov. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Credelio™ CAT (lotilaner) to treat New World screwworm (NWS) infestations in cats. This authorization represents the first EUA granted by the FDA for New World screwworm treatment in felines.

As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.

INDIANAPOLIS , Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, December 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference at 12:30 p.m.

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS , Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to create and scale new companies at the convergence of animal, plant and human health in partnership with  Elanco Animal Health (NYSE: ELAN). Located in the OneHealth Innovation District at Elanco's new global headquarters in Indianapolis, the studio will unite research institutions, investors, corporate partners and entrepreneurs to accelerate the next generation of innovation and launch new startups based in Indiana.

Jeff Simmons, Elanco Animal Health CEO, joins 'The Exchange' to discuss what's driving the company's earnings results, where the company's is devoting the most resources and much more.

Elanco Animal Health Incorporated ( ELAN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tiffany Kanaga Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Linda Bolduc - Morgan Stanley, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Andrew Dusing - Cleveland Research Company LLC Presentation Operator Ladies and gentlemen, thank you for standing by.

The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.